ESR1 and breast cancer: Paradoxically, PI3KCA mutations are favourable prognostic markers of PFS [139,140] for ER+/HER2+ BC patients, and despite high levels of PI3K/AKT signalling, they appear to be associated with reduced mTORC1 activity [140].